<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIM: To evaluate whether there is a cutoff value for a metabolite concentration measured by 1 H <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> spectroscopy (MRS), which can be used to differentiate malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> (high-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo>, primary <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> [PCNSL] and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>) from other contrast-enhancing lesions like low-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo> and non-neoplastic lesions </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: 1 H MRS was performed in 252 consecutive patients with space-occupying <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> which were enhanced with application of a contrast agent </plain></SENT>
<SENT sid="2" pm="."><plain>Concentrations of N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-<z:chebi fb="0" ids="29995">aspartate</z:chebi>, total <z:chebi fb="2" ids="16919">creatine</z:chebi>, <z:chebi fb="3" ids="15354">choline</z:chebi> containing metabolites (total <z:chebi fb="3" ids="15354">choline</z:chebi>, tCho), <z:chebi fb="23" ids="18059">lipids</z:chebi>, and <z:chebi fb="4" ids="24996">lactate</z:chebi> were evaluated from the contrast-enhancing part of the lesions and from the <z:mpath ids='MPATH_458'>normal</z:mpath> appearing brain tissue </plain></SENT>
<SENT sid="3" pm="."><plain>Linear discriminant analysis was used to find the best predictor for malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, receiver operating characteristic analysis (ROC) was performed to determine a cutoff value for the best predictor in detecting malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> with a specificity of &gt;95% </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> <z:mp ids='MP_0009277'>brain tumors</z:mp> and 20 out of 47 nonneoplastic lesions were examined histopathologically </plain></SENT>
<SENT sid="6" pm="."><plain>The remaining 27 diagnoses were based on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging, clinical findings, and follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>The final diagnosis was 134 high-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo> (WHO grade III/IV), 36 metastases, 9 PCNSL, 8 low-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo> (WHO grade I/II), 34 infections, 9 infarctions, 2 <z:mp ids='MP_0008817'>hematomas</z:mp>, and 2 vasculitides </plain></SENT>
<SENT sid="8" pm="."><plain>18 patients were excluded due to insufficient spectral quality </plain></SENT>
<SENT sid="9" pm="."><plain>The tCho concentration was the best predictor to differentiate malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> from enhancing low-grade <z:hpo ids='HP_0009733'>gliomas</z:hpo> or non-neoplastic lesions (F=26.6 [df: 25.833], p&lt;0.0005) </plain></SENT>
<SENT sid="10" pm="."><plain>The ROC revealed that a cutoff tCho value, based on an increase of â‰¥40% compared to <z:mpath ids='MPATH_458'>normal</z:mpath>, yielded a specificity of 100% and a sensitivity of 89.4% to correctly diagnose a malignant <z:mp ids='MP_0009277'>brain tumor</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: 1 H MRS reliably differentiates malignant <z:mp ids='MP_0009277'>brain tumors</z:mp> from other contrast-enhancing <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>At least a 40% increase of tCho compared to <z:mpath ids='MPATH_458'>normal</z:mpath> brain tissue indicates a <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> (WHO grade III/IV <z:hpo ids='HP_0009733'>gliomas</z:hpo>, PCNSL, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>) with &gt;90% specificity and sensitivity </plain></SENT>
</text></document>